Drug-Drug Interactions Between Raltegravir and Pravastatin in Healthy Volunteers

• DOI: 10.1097/qai.0b013e3181d9a354
• Publication Date: 2010-04-15T10:58:40Z
• Authors: Matthijs van Luin; Angela Colbers; Eleonora W J van ...; Corrien P W G M V...; Bas Schouwenberg; Arjen Hoitsma; Hugo G da Silva; David M Burger
• Keywords: Raltegravir; Integrase inhibitor

To evaluate the potential drug-drug interaction between raltegravir and pravastatin.This was an open-label, randomized, 3-period, cross-over, single-centre trial in 24 healthy volunteers. Subjects received following treatments: pravastatin 40 mg every day for 4 days, 400 twice a + days. The treatments were separated by washout periods of 10 On each treatment period, blood samples pharmacokinetics collected throughout 24-hour period.Geometric mean ratios (90% confidence interval) versus alone 0.96 (0.83 to 1.11) AUC0-24 1.04 (0.85 1.26) Cmax. low-density lipoprotein cholesterol decrease after days 0.42 mmol/L both presence absence raltegravir. geometric ratio AUC0-12, Cmax, C12 1.13 (0.77 1.65), 1.31 (0.81 2.13), 0.59 (0.39 0.88), respectively.Raltegravir did not influence or short-term lipid-lowering effects pravastatin, whereas increased Cmax but decreased on are likely be clinically relevant.